TBPH NASDAQ
Theravance Biopharma, Inc.
1W: -1.0%
1M: -1.4%
3M: -16.9%
YTD: -10.0%
1Y: +72.9%
3Y: +47.1%
5Y: -12.7%
$16.37
+0.03 (+0.18%)
After Hours: $15.98 (-0.39, -2.38%)
Weekly Expected Move ±3.0%
$15
$16
$16
$17
$17
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$107M
+66.9% ▲
5Y CAGR: +8.4%
Gross Profit
$102M
+58.4% ▲
5Y CAGR: +7.2%
Operating Income
-$13M
+71.8% ▲
Net Income
$106M
+287.7% ▲
EPS (Diluted)
$2.06
+279.1% ▲
EBITDA
-$8M
+79.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $55M | $51M | $57M | $64M | $107M |
| YoY Growth | -23.0% | -7.2% | +11.8% | +12.1% | +66.9% |
| Cost of Revenue | $194M | $63M | $41M | $0 | $6M |
| Gross Profit | -$138M | -$12M | $17M | $64M | $102M |
| Gross Margin | -250.1% | -23.5% | 29.3% | 100.0% | 94.9% |
| R&D Expenses | $202M | $70M | $46M | $38M | $37M |
| SG&A Expenses | $0 | $67M | $70M | $69M | $74M |
| Operating Expenses | $119M | $80M | $73M | $111M | $115M |
| Operating Income | -$258M | -$92M | -$56M | -$47M | -$13M |
| Operating Margin | -466.1% | -179.1% | -97.6% | -72.9% | -12.3% |
| Interest Expense | $9M | $6M | $2M | $3M | $2M |
| Income Before Tax | -$265M | -$93M | -$49M | -$45M | $129M |
| Tax Expense | -$151K | $9K | $6M | $12M | $23M |
| Net Income | -$199M | $872M | -$55M | -$56M | $106M |
| Net Margin | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
| EPS (Diluted) | $-2.87 | $-1.26 | $-1.00 | $-1.15 | $2.06 |
| EBITDA | -$233M | -$76M | -$52M | -$38M | -$8M |
| Shares Outstanding | 69M | 74M | 55M | 49M | 52M |